SYRE Stock Forecast & Price Target

Spyre Therapeutics is viewed favorably because its pipeline combines three differentiated, extended half-life antibodies—anti-α4β7, anti-TL1A, and anti-IL-23—that appear well suited for additive efficacy, convenient infrequent dosing, and potentially best-in-class inflammatory bowel disease regimens. Recent clinical evidence strengthens that thesis: ABBV-466 showed higher endoscopic remission than comparator monotherapies at 12wk and 24wk with comparable safety, while SPY003 met its primary endpoint in the Part A induction SKYLINE trial (n=44) with a -10.0 RHI change and 20% clinical remission. Expansion into rheumatology and hidradenitis suppurativa also adds optionality in large, undertreated markets where differentiated biologics could support meaningful commercial upside.

Spyre Therapeutics is a clinical-stage company whose value depends heavily on tulisokibart and other early pipeline assets, leaving it exposed to binary trial outcomes and regulatory uncertainty. Although Phase 2b HS data showed dose-response and competitive efficacy versus Bimzelx, the program is still far from commercialization, and even in this study serious adverse events occurred in 2.4% to 4.8% of patients across treatment groups. The company also faces financing risk because it will need to access capital markets to complete development and commercialization, which could dilute shareholders if funding conditions tighten.